A Phase 4 interventional study of Apixaban in Anticoagulation, sponsored by Bristol-Myers Squibb. Completed at 20 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this protocol is to evaluate the safety of Apixaban in prophylaxis of Venous Thromboembolism (VTE) in Indian patients undergoing elective total knee or hip replacement
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apixaban 2.5 mg tablets by mouth twice daily, 12 days for TKR subjects or 35 days for THR subjects
Drug: Apixaban
Also known as: Eliquis, BMS-562247
Number of Participants With Composite of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding/Clinically Relevant Non-major Bleeding (CRNM) While Undergoing Elective TKR or THR at the End of Treatment + 2 Days
TKR = Total knee replacement; THR = Total hip replacement. ISTH major bleeding is 1) Fatal or 2) Bleeding in a critical organ, such as brain, spine, eye, retroperitoneum, joint, heart sac, or skeletal muscle (and resulting in compartment syndrome), or 3) Bleeding that results in a fall of hemoglobin of 2 g/dL or more or transfusion of 2 units or more of packed red cells or whole blood within 24 hours. CRNM bleeding is bleeding that 1) Is clinically acute and overt 2) Does not satisfy criteria as a major bleed but requires medical intervention, such as a visit to a physician's office, emergency room, or urgent care center for epistaxis
Time frame: 2 weeks + 2 days for TKR, 5 weeks + 2 days for THR
Number of Participants With Composite of Venous Thromboembolism (VTE)/All Cause Death at the End of Treatment + 2 Days
VTE is the combination of deep vein thrombosis and non-fatal pulmonary embolism.
Time frame: 2 weeks + 2 days for TKR, 5 weeks + 2 days for THR
This study was conducted in an Indian orthopedic population.
| Milestone | Total Knee Replacement (TKR) | Total Hip Replacement (THR) |
|---|---|---|
| Started | 326 | 172 |
| Continuing into follow-up period | 324 | 171 |
| Completed | 322 | 170 |
| Not completed | 4 | 2 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Subj. request to discont. treatment | 2 | 0 |
| Milestone | Total Knee Replacement (TKR) | Total Hip Replacement (THR) |
|---|---|---|
| Started | 324 | 171 |
| Completed | 323 | 170 |
| Not completed | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
TKR = Total knee replacement; THR = Total hip replacement. ISTH major bleeding is 1) Fatal or 2) Bleeding in a critical organ, such as brain, spine, eye, retroperitoneum, joint, heart sac, or skeletal muscle (and resulting in compartment syndrome), or 3) Bleeding that results in a fall of hemoglobin of 2 g/dL or more or transfusion of 2 units or more of packed red cells or whole blood within 24 hours. CRNM bleeding is bleeding that 1) Is clinically acute and overt 2) Does not satisfy criteria as a major bleed but requires medical intervention, such as a visit to a physician's office, emergency room, or urgent care center for epistaxis
| Participants | Total Knee Replacement (TKR) | Total Hip Replacement (THR) |
|---|---|---|
| Major Bleeding | 0 | 0 |
| Clinically Relevant Non-Major Bleeding | 0 | 1 |
| Major or Clinically Relevant Non-Major Bleeding | 0 | 1 |
| Any Bleeding | 0 | 1 |
VTE is the combination of deep vein thrombosis and non-fatal pulmonary embolism.
| Participants | Total Knee Replacement (TKR) | Total Hip Replacement (THR) |
|---|---|---|
| Number of Participants With Composite of Venous Thromboembolism (VTE)/All Cause Death at the End of Treatment + 2 Days | 1 | 1 |
Collected over AEs are assessed from Day 1 through Day 42 +/- 2 days for Total Knee Replacement Participants; AEs are assessed from Day 1 through Day 65 +/-2 days for Total Hip Replacement Participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TOTAL KNEE REPLACEMENT (TKR) | 0/326 (0%) | 2/326 (0.6%) | 23/326 (7.1%) |
| TOTAL HIP REPLACEMENT (THR) | 0/172 (0%) | 0/172 (0%) | 6/172 (3.5%) |
| Event | TOTAL KNEE REPLACEMENT (TKR) | TOTAL HIP REPLACEMENT (THR) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/326 | 0/172 |
| VertigoEar and labyrinth disorders | 1/326 | 0/172 |
| Deep vein thrombosisVascular disorders | 1/326 | 0/172 |
| Event | TOTAL KNEE REPLACEMENT (TKR) | TOTAL HIP REPLACEMENT (THR) |
|---|---|---|
| Incision site painInjury, poisoning and procedural complications | 23/326 | 6/172 |
| Age, Continuous(Years) | Total Knee Replacement (TKR) | Total Hip Replacement (THR) | Total |
|---|---|---|---|
| Mean | 60.7 ± 9.59 | 41.7 ± 13.30 | 54.1 ± 11.01 |
| Sex: Female, Male(Participants) | Total Knee Replacement (TKR) | Total Hip Replacement (THR) | Total |
|---|---|---|---|
| Female | 237 | 53 | 290 |
| Male | 89 | 119 | 208 |
| Ethnicity (NIH/OMB)(Participants) | Total Knee Replacement (TKR) | Total Hip Replacement (THR) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 9 | 12 |
| Not Hispanic or Latino | 322 | 163 | 485 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Total Knee Replacement (TKR) | Total Hip Replacement (THR) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 326 | 172 | 498 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Jun 2018, 38 months.
Results were first posted in Sep 2019, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban